TG Therapeutics Inc

-0.21 (-1.41%)
7:44:27 PM EDT: $14.70 0.00 (0.00%)

TG Therapeutics Initiates Rolling Submission Of Biologics License Application To U.S. FDA For Ublituximab In Combination With Umbralisib As A Treatment For Patients With Chronic Lymphocytic Leuk

Published: 12/01/2020 12:27 GMT
TG Therapeutics Inc (TGTX) - Tg Therapeutics Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration for Ublituximab in Combination With Umbralisib As a Treatment for Patients With Chronic Lymphocytic Leukemia.
Tg Therapeutics Inc - Co Expects to Complete Bla Rolling Submission in First Half of 2021.